A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

Trial Profile

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs MEDI 6469 (Primary) ; Durvalumab; Rituximab; Tremelimumab
  • Indications Diffuse large B cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 27 Mar 2017 Status changed from completed to discontinued.
    • 02 May 2016 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2015 Planned End Date changed from 1 Oct 2017 to 1 Jan 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top